Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Chemo-immunotherapy in advanced head and neck cancer
Autore:
Recchia, F; Sica, G; De Filippis, S; Rosselli, M; Pompili, P; Saggio, G; Rea, S;
Indirizzi:
Osped Civile, Div Oncol, Avezzano, Italy Osped Civile Avezzano ItalyOsped Civile, Div Oncol, Avezzano, Italy Ctr Riferimento Oncol Franco Italiano, Monterotondo, Italy Ctr RiferimentoOncol Franco Italiano Monterotondo Italy rotondo, Italy Catholic Univ Sacred Heart, Ist Istol & Embriol, I-00168 Rome, Italy Catholic Univ Sacred Heart Rome Italy I-00168 briol, I-00168 Rome, Italy Univ Aquila, I-67100 Laquila, Italy Univ Aquila Laquila Italy I-67100Univ Aquila, I-67100 Laquila, Italy
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 1B, volume: 19, anno: 1999,
pagine: 773 - 777
SICI:
0250-7005(199901/02)19:1B<773:CIAHAN>2.0.ZU;2-E
Fonte:
ISI
Lingua:
ENG
Soggetto:
SQUAMOUS-CELL CARCINOMA; VITAMIN-A; RECURRENT HEAD; ONCOLOGY-GROUP; II TRIAL; THYMOSTIMULIN; CHEMOTHERAPY; CISPLATIN; RETINOIDS; DIFFERENTIATION;
Keywords:
head and neck cancer; chemotherapy; retinoids; thymopentin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Recchia, F Via Rossetti 1, I-67056 Luco Dei Marsi, AQ, Italy Via Rossetti1 Luco Dei Marsi AQ Italy I-67056 arsi, AQ, Italy
Citazione:
F. Recchia et al., "Chemo-immunotherapy in advanced head and neck cancer", ANTICANC R, 19(1B), 1999, pp. 773-777

Abstract

Background: Patients with advanced squamous cell carcinoma of the head andneck (SCC) have a depressed immune system whose function is worsened by chemotherapy. In a pilot phase II study in order to improve the immune function during chemotherapy, we combined to cisplatin (CDDP) and 5-fluorouracil (5-FU) two biological response modifiers, retinyl palmitate (R) and Thymopentin (TP-5) for the treatment of SCC. Patients and methods: Fifty patients with recurrent or metastatic SCC of the head and neck were treated with Cisplatin 24 mg/m(2) from day I to 5 and 5-FU 1,000 mg/m(2) by a 120 hour continuous infusion. Retinyl palmitate was administer ed orally 50,000 lu b.i.dand Thymopentin 50 mg subcutaneously 3 times a week. Results: Chemotherapytreatment was well tolerated with G3 hematological toxicity in 30% of patients and G2 gastrointestinal toxicity in 20% of patients. 16 patients (32%)had a complete response (CR), 13 patients had partial response (PR) (26%),(response rate 58%, 95% c.i. 43%-72%); stable disease (SD) was observed in7 patients (14%), while 14 patients progressed (PD) (28%). Median time to progression was 12 months (range 2.8-94.5), Median overall survival was 13.5 months (range 2-104). Conclusions: The association of CDDP and 5-FU with Retinyl Palmitate and TP5 has a major activity in the treatment of advancedhead and neck cancer and a relatively well tolerated toxicity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 11/07/20 alle ore 07:41:48